Recent Company News

• 03:03 PM ET Apr 29, 2025
  

  Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at AACR 2025 (€1.84, 0.00)

• 01:38 AM ET Apr 24, 2025
  

  Innate Pharma closes €15M investment by Sanofi (€1.80, 0.00)

• 01:09 AM ET Apr 23, 2025
  

  Innate Pharma announce review of their January 2016 Research Collaboration and License agreement with Sanofi: (€1.72, 0.00)

• 04:14 AM ET Feb 17, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 09:16 AM ET Mar 27, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:27 AM ET Mar 27, 2025
  

  StreetAccount Summary - US Pre-market trading

• 02:04 AM ET Mar 27, 2025
  

  Innate Pharma reports FY net loss from cont ops (€49.5M) vs FactSet (€21.5M) [3 est, (€42)-17.3M]; pleased to extend cash runway to mid-2026 (€1.86, 0.00)

• 02:05 AM ET Mar 26, 2025
  

  Innate Pharma announces abstract regarding IPH4502 selected for AACR Annual Meeting 2025; CEO Dickinson to give an update on Innate's pipeline and strategy (€1.84, 0.00)

• 02:58 AM ET Feb 17, 2025
  

  StreetAccount Summary - European pre-market trading update